Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Developing a new treatment and companion diagnostic to improve outcomes for glioblastoma patients

Obiettivo

Glioblastoma (GBM) remains a devastating brain cancer with limited treatment advances and poor survival outcomes. The GLIOBREAK project aims to develop BEA-17, a first-in-class oral small molecule that degrades epigenetic regulators LSD1 and CoREST, thereby reversing GBM immune evasion and enhancing responsiveness to immunotherapy.

The main objectives are to advance BEA-17 and its biomarker-driven companion diagnostic from validated laboratory stage (TRL4) to early clinical readiness (TRL6). This will be achieved through scalable GMP manufacturing, GLP-compliant safety and pharmacokinetic studies, efficacy validation in preclinical models, biomarker discovery and validation, and regulatory preparation including orphan drug designation.

GLIOBREAK directly addresses key challenges outlined in the EICT work programme by proposing a novel immuno-epigenetic therapy targeting GBM’s immunosuppressive microenvironment, combined with precision biomarker-based patient stratification to improve clinical outcomes. This aligns with Europe’s Beating Cancer Plan and EU priorities for innovative, personalized oncology medicines.

By integrating fundamental biological insights with cutting-edge therapeutic and diagnostic development, GLIOBREAK aims to deliver a transformative new treatment option for GBM patients and establish a platform for expanding into other difficult-to-treat cancers, reinforcing Europe’s leadership in precision immuno-oncology.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-EIC - HORIZON EIC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-EIC-2025-TRANSITIONOPEN

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

BEACTICA THERAPEUTICS AB
Contributo netto dell'UE
€ 1 643 722,19
Indirizzo
VIRDINGS ALLE 2
754 50 Uppsala
Svezia
PMI
Sì
Regione
Östra Sverige Östra Mellansverige Uppsala län
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
Nessun dato

Partecipanti (1)